- Home
- BRIA vs ASMB Comparison
BRIA vs ASMB Comparison
Compare BRIA & ASMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BRIA
- ASMB
- Stock Information
- Founded
- BRIA 2011
- ASMB 2005
- Country
- BRIA Singapore
- ASMB United States
- Employees
- BRIA N/A
- ASMB N/A
- Industry
- BRIA
- ASMB Biotechnology: Pharmaceutical Preparations
- Sector
- BRIA
- ASMB Health Care
- Exchange
- BRIA NYSE
- ASMB Nasdaq
- Market Cap
- BRIA 99.8M
- ASMB 93.7M
- IPO Year
- BRIA 2024
- ASMB 2010
- Fundamental
- Price
- BRIA $3.65
- ASMB $14.49
- Analyst Decision
- BRIA
- ASMB Buy
- Analyst Count
- BRIA 0
- ASMB 2
- Target Price
- BRIA N/A
- ASMB $35.00
- AVG Volume (30 Days)
- BRIA 38.6K
- ASMB 38.9K
- Earning Date
- BRIA 02-15-2025
- ASMB 11-07-2024
- Dividend Yield
- BRIA N/A
- ASMB N/A
- EPS Growth
- BRIA N/A
- ASMB N/A
- EPS
- BRIA 92.24
- ASMB N/A
- Revenue
- BRIA $55,755,669.00
- ASMB $28,326,000.00
- Revenue This Year
- BRIA N/A
- ASMB $282.16
- Revenue Next Year
- BRIA N/A
- ASMB N/A
- P/E Ratio
- BRIA $0.04
- ASMB N/A
- Revenue Growth
- BRIA 8.03
- ASMB N/A
- 52 Week Low
- BRIA $3.21
- ASMB $9.48
- 52 Week High
- BRIA $4.38
- ASMB $19.93
- Technical
- Relative Strength Index (RSI)
- BRIA N/A
- ASMB 40.72
- Support Level
- BRIA N/A
- ASMB $14.17
- Resistance Level
- BRIA N/A
- ASMB $15.73
- Average True Range (ATR)
- BRIA 0.00
- ASMB 1.02
- MACD
- BRIA 0.00
- ASMB -0.21
- Stochastic Oscillator
- BRIA 0.00
- ASMB 8.72
About BRIA BRILLIA INC
BrilliA Inc is engaged in business of sales and marketing of lingerie's products including bra, panty and body suit, mainly serving the American, European and other markets.
About ASMB Assembly Biosciences Inc.
Assembly Biosciences Inc is a clinical-stage biotechnology company. It is advancing two innovative platform programs, a novel class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection and novel class of oral synthetic live biotherapeutics, which are designed to restore health to a dysbiotic microbiome. The company's HBV-cure program is aimed at increasing the current low cure rate for patients with HBV and is pursuing multiple drug candidates that inhibit multiple steps of the HBV lifecycle. Assembly has discovered several novel core protein Allosteric Modulators, which are small molecules that directly target and allosterically modulate the HBV core protein. The majority of the revenue is generated from the HBV cure program.